Meitheal Pharmaceuticals is pleased to announce that we have launched Bupivacaine Hydrochloride Injection, USP 0.25% (2.5 mg/mL), 0.5% (5 mg/mL), and 0.75% (7.5 mg/mL) Single-Dose Vials in 30mL and 10mL presentations. Meitheal will offer these Single-Dose Vials of Bupivacaine Hydrochloride in a pack of 1 vial for all 6 presentations. Meitheal previously launched Bupivacaine Hydrochloride Injection, USP 0.25% (2.5 mg/mL) and 0.5% (5 mg/mL) Multi-Dose Vials in 2023.
As of March 12, 2024, both the FDA and the ASHP websites list multiple presentations of Bupivacaine on drug shortage.
“We are pleased to bring Single-Dose Bupivacaine to the United States Market during a time of product shortage,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “At Meitheal, we understand how important it is to have a reliable supply. Expanding our offering by now having both Single-Dose and Muli-Dose Vials is just one more example of our ability to follow through on our commitment to our customers and their patients' needs.”
Meitheal’s Corporate Purpose is to “Simplify access to life changing medicine, for good.” In September 2023, Meitheal announced the expansion of its generic injectable products through an asset purchase agreement through its parent company and is anticipating launch of additional products that can help make a positive impact on drug shortages.
ABOUT BUPIVACAINE HYDROCHOLORIDE INJECTION, USP
Bupivacaine Hydrochloride Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of Bupivacaine Hydrochloride Injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia.
For full prescribing information, please click on the following link.
Learn more about Bupivacaine Hydrochloride Injection, USP
